Q4 2022 13F Holders as of 12/31/2022
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
71.4M
-
Number of holders
-
83
-
Total 13F shares, excl. options
-
28.2M
-
Shares change
-
-1.97M
-
Total reported value, excl. options
-
$317M
-
Value change
-
-$21.7M
-
Put/Call ratio
-
1.42
-
Number of buys
-
40
-
Number of sells
-
-37
-
Price
-
$11.22
Significant Holders of Phathom Pharmaceuticals, Inc. - Common Stock (PHAT) as of Q4 2022
99 filings reported holding PHAT - Phathom Pharmaceuticals, Inc. - Common Stock as of Q4 2022.
Phathom Pharmaceuticals, Inc. - Common Stock (PHAT) has 83 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 28.2M shares
of 71.4M outstanding shares and own 39.53% of the company stock.
Largest 10 shareholders include Frazier Life Sciences Management, L.P. (8.41M shares), Medicxi Ventures Management (Jersey) Ltd (2.48M shares), Invesco Ltd. (2.21M shares), Avidity Partners Management LP (1.9M shares), Ensign Peak Advisors, Inc (1.76M shares), BlackRock Inc. (1.69M shares), Abingworth LLP (1.44M shares), 683 Capital Management, LLC (1.35M shares), VANGUARD GROUP INC (1.08M shares), and GW&K Investment Management, LLC (594K shares).
This table shows the top 83 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.